Ernexa Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on July 1, 2027. The record date for the meeting was May 6, 2026. As of the record date, there were 1,166,333 shares of common stock issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A quorum was established with 619,741 shares (approximately 53.13% of outstanding shares) represented. Three proposals were voted upon:
- Proposal 1 (Election of Directors): All five nominees were elected to the Board of Directors.
- James Bristol: 455,380 For, 3,196 Withheld, 161,165 Non-Votes
- Peter Cicala: 455,121 For, 3,455 Withheld, 161,165 Non-Votes
- Sanjeev Luther: 442,564 For, 16,012 Withheld, 161,165 Non-Votes
- Elena Ratner: 455,633 For, 2,943 Withheld, 161,165 Non-Votes
- William Wexler: 455,156 For, 3,420 Withheld, 161,165 Non-Votes
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Haskell & White LLP as the independent registered public accounting firm for the 2026 fiscal year.
- Votes: 590,236 For, 29,010 Against, 495 Abstentions, 0 Non-Votes
- Proposal 3 (Equity Incentive Plan): Stockholders approved the adoption of the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan.
- Votes: 363,640 For, 94,840 Against, 96 Abstentions, 161,165 Non-Votes
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the terms and share limits of the newly adopted 2026 Omnibus Equity Incentive Plan (Exhibit 10.1).
- Confirm the tenure of the newly elected directors, who serve until the 2027 Annual Meeting.
- Note the significant number of broker non-votes (161,165) on director elections and the equity plan, indicating shares held in street name where brokers lacked discretionary voting authority.
- Review the full text of the Equity Incentive Plan to assess potential dilution impacts.